1136 related articles for article (PubMed ID: 12473604)
41. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Honma I; Torigoe T; Hirohashi Y; Kitamura H; Sato E; Masumori N; Tamura Y; Tsukamoto T; Sato N
J Transl Med; 2009 Dec; 7():103. PubMed ID: 20003233
[TBL] [Abstract][Full Text] [Related]
42. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
[TBL] [Abstract][Full Text] [Related]
43. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.
Fujie T; Tahara K; Tanaka F; Mori M; Takesako K; Akiyoshi T
Int J Cancer; 1999 Jan; 80(2):169-72. PubMed ID: 9935194
[TBL] [Abstract][Full Text] [Related]
44. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
45. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
46. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Salgaller ML; Lodge PA; McLean JG; Tjoa BA; Loftus DJ; Ragde H; Kenny GM; Rogers M; Boynton AL; Murphy GP
Prostate; 1998 May; 35(2):144-51. PubMed ID: 9568678
[TBL] [Abstract][Full Text] [Related]
47. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
[TBL] [Abstract][Full Text] [Related]
49. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells.
Takenoyama M; Yoshino I; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1998 Jan; 89(1):60-6. PubMed ID: 9510477
[TBL] [Abstract][Full Text] [Related]
50. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.
Akiyama Y; Maruyama K; Mochizuki T; Sasaki K; Takaue Y; Yamaguchi K
Immunol Lett; 2002 Aug; 83(1):21-30. PubMed ID: 12057851
[TBL] [Abstract][Full Text] [Related]
51. Analysis of HLA-A24-restricted peptides of carcinoembryonic antigen using a novel structure-based peptide-HLA docking algorithm.
Nakamura Y; Tai S; Oshita C; Iizuka A; Ashizawa T; Saito S; Yamaguchi S; Kondo H; Yamaguchi K; Akiyama Y
Cancer Sci; 2011 Apr; 102(4):690-6. PubMed ID: 21231985
[TBL] [Abstract][Full Text] [Related]
52. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B
J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
[TBL] [Abstract][Full Text] [Related]
53. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
Bae J; Hideshima T; Zhang GL; Zhou J; Keskin DB; Munshi NC; Anderson KC
Leukemia; 2018 Mar; 32(3):752-764. PubMed ID: 29089645
[TBL] [Abstract][Full Text] [Related]
54. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
55. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
Harada M; Ishihara Y; Itoh K; Yamanaka R
Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
57. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
58. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
Ohminami H; Yasukawa M; Fujita S
Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
[TBL] [Abstract][Full Text] [Related]
59. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
60. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]